Wall Street analyst estimates for AptarGroup, Inc. (ATR): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage.
Consensus price target
$148.33 (+8 % vs price $137.20)
between $135.00 and $160.00 · 3 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $4.0B | $4.0B – $4.0B | $5.49 | 6 |
| 2027E | $4.1B | $4.1B – $4.2B | $6.18 | 6 |
Figures in USD · consensus as of October 28, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 7 |
| Sell | 3 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (−2 sell to +2 buy) | 0.28 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-29 | $1.47 | ||
| 2026-07-30 | $1.42 | $1.35 | +5.2% |
| 2026-04-30 | $1.19 | $1.15 | +3.5% |
| 2026-02-05 | $1.25 | $1.24 | +0.8% |
| 2025-10-30 | $1.62 | $1.57 | +3.2% |
| 2025-07-31 | $1.66 | $1.58 | +5.1% |
| 2025-05-01 | $1.20 | $1.16 | +3.4% |
| 2025-02-06 | $1.52 | $1.28 | +18.8% |
Valuation Ratios
| P/E Ratio | 24.81 |
| Price / Book | 310.73 |
| EV / EBITDA | 13.05 |
| Dividend Yield | 1.40% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.33B | $2.47B | $2.76B | $2.86B | $2.93B | $3.23B | $3.32B | $3.49B | $3.58B | $3.78B |
| Cost of Revenue | $1.50B | $1.60B | $1.81B | $1.82B | $1.84B | $2.07B | $2.16B | $2.22B | $2.23B | $2.66B |
| Gross Profit | $832.9M | $865.1M | $951.8M | $1.04B | $1.09B | $1.16B | $1.16B | $1.26B | $1.36B | $1.12B |
| Research & Development | $66.2M | $68.2M | $75.3M | $82.8M | $92.5M | $99.8M | 0 | 0 | 0 | $105.1M |
| Selling, General & Admin | $367.6M | $388.3M | $430.0M | $454.6M | $500.2M | $551.2M | $544.3M | $565.8M | $582.2M | $499.9M |
| Operating Expenses | $522.4M | $541.4M | $601.7M | $649.2M | $747.0M | $809.3M | $784.6M | $859.4M | $859.0M | $605.0M |
| Operating Income | $310.5M | $321.5M | $286.3M | $371.7M | $339.5M | $347.3M | $379.3M | $404.0M | $496.5M | $512.3M |
| EBITDA | $470.5M | $490.1M | $475.6M | $572.1M | $556.2M | $586.8M | $609.4M | $663.8M | $777.4M | $831.5M |
| Interest Expense | $35.2M | $40.6M | $32.6M | $35.5M | $33.2M | $30.3M | $40.8M | $40.4M | $43.9M | $52.7M |
| Pre-tax Income | $280.5M | $294.8M | $266.0M | $342.1M | $301.2M | $321.7M | $334.7M | $374.8M | $469.8M | $491.4M |
| Income Tax | $74.9M | $74.8M | $71.3M | $99.8M | $87.1M | $78.0M | $95.1M | $90.6M | $95.6M | $98.9M |
| Net Income | $205.6M | $220.0M | $194.7M | $242.2M | $214.0M | $244.1M | $239.3M | $284.5M | $374.5M | $392.8M |
| EPS | $3.27 | $3.52 | $3.12 | $3.81 | $3.32 | $3.72 | $3.66 | $4.34 | $5.65 | $5.97 |
| EPS (Diluted) | $3.17 | $3.41 | $3.00 | $3.66 | $3.21 | $3.60 | $3.59 | $4.25 | $5.53 | $5.88 |
| Shares Outstanding (Diluted) | 64.8 M | 64.6 M | 65.0 M | 66.2 M | 66.7 M | 67.7 M | 66.7 M | 66.9 M | 67.7 M | 66.7 M |
Price
| Price | $137.20 (closing price, October 30, 2026) |
| Market Cap | $8.7B |
| Exchange | NYSE |
| Country | US |
Related companies: AMCR · WST · SON · SLGN · STVN
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of ATR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks